EP2504331A4 - Composé, certaines nouvelles formes de celui-ci, compositions pharmaceutiques de celui-ci et procédés de préparation et d'utilisation - Google Patents

Composé, certaines nouvelles formes de celui-ci, compositions pharmaceutiques de celui-ci et procédés de préparation et d'utilisation

Info

Publication number
EP2504331A4
EP2504331A4 EP10831161.4A EP10831161A EP2504331A4 EP 2504331 A4 EP2504331 A4 EP 2504331A4 EP 10831161 A EP10831161 A EP 10831161A EP 2504331 A4 EP2504331 A4 EP 2504331A4
Authority
EP
European Patent Office
Prior art keywords
compound
preparation
methods
pharmaceutical compositions
new forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10831161.4A
Other languages
German (de)
English (en)
Other versions
EP2504331B1 (fr
EP2504331A1 (fr
Inventor
Wei-Guo Su
Weihan Zhang
Hong Jia
Yumin Cui
Yongxin Ren
Yang Sai
Zhenping Wu
Wenji Li
Jiangyong Shao
Zhenping Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44029398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2504331(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Priority to PL10831161T priority Critical patent/PL2504331T3/pl
Publication of EP2504331A1 publication Critical patent/EP2504331A1/fr
Publication of EP2504331A4 publication Critical patent/EP2504331A4/fr
Application granted granted Critical
Publication of EP2504331B1 publication Critical patent/EP2504331B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
EP10831161.4A 2009-11-23 2010-11-23 Composé, certaines nouvelles formes de celui-ci, compositions pharmaceutiques de celui-ci et procédés de préparation et d'utilisation Active EP2504331B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL10831161T PL2504331T3 (pl) 2009-11-23 2010-11-23 Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009101992592A CN102070618B (zh) 2009-11-23 2009-11-23 一种化合物及其晶体
PCT/CN2010/078997 WO2011060746A1 (fr) 2009-11-23 2010-11-23 Composé, certaines nouvelles formes de celui-ci, compositions pharmaceutiques de celui-ci et procédés de préparation et d'utilisation

Publications (3)

Publication Number Publication Date
EP2504331A1 EP2504331A1 (fr) 2012-10-03
EP2504331A4 true EP2504331A4 (fr) 2013-04-17
EP2504331B1 EP2504331B1 (fr) 2014-11-12

Family

ID=44029398

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10831161.4A Active EP2504331B1 (fr) 2009-11-23 2010-11-23 Composé, certaines nouvelles formes de celui-ci, compositions pharmaceutiques de celui-ci et procédés de préparation et d'utilisation

Country Status (19)

Country Link
US (2) US8658658B2 (fr)
EP (1) EP2504331B1 (fr)
JP (1) JP5758399B2 (fr)
KR (1) KR101513784B1 (fr)
CN (2) CN102070618B (fr)
AU (1) AU2010321366B2 (fr)
BR (1) BR112012012138B1 (fr)
CA (1) CA2781066C (fr)
DK (1) DK2504331T3 (fr)
ES (1) ES2529105T3 (fr)
IN (1) IN2012DN04868A (fr)
MX (1) MX2012005926A (fr)
MY (1) MY161749A (fr)
NZ (1) NZ600266A (fr)
PH (1) PH12012500992A1 (fr)
PL (1) PL2504331T3 (fr)
PT (1) PT2504331E (fr)
RU (1) RU2507203C1 (fr)
WO (1) WO2011060746A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070618B (zh) * 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体
US9776986B2 (en) * 2014-06-19 2017-10-03 Merial Inc. Parasiticidal compositions comprising indole derivatives, methods and uses thereof
CN105985326B (zh) * 2015-02-16 2020-04-14 上海宣创生物科技有限公司 嘧啶衍生物晶型ⅲ及其制备方法和用途
WO2016187767A1 (fr) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Compositions pharmaceutiques et utilisation de celles-ci
WO2018090324A1 (fr) * 2016-11-18 2018-05-24 Hutchison Medipharma Limited Procédé de traitement de tumeurs solides
JP2020164434A (ja) * 2019-03-28 2020-10-08 上野製薬株式会社 ２，６−ナフタレンビス（２−オキサゾリン）の製造方法
TW202143969A (zh) * 2020-03-09 2021-12-01 大陸商和記黃埔醫藥（上海）有限公司 抗ｐｄ－１抗體和多受體酪胺酸激酶抑制劑的藥物組合及其使用方法
JP2024515630A (ja) * 2021-04-12 2024-04-10 ミトイミューン・セラピューティクス・インコーポレイテッド ５－［（１，１－ジオキシド－４－チオモルホリニル）メチル］－２－フェニル－ｎ－（テトラヒドロ－２ｈ－ピラン－４－イル）－１ｈ－インドール－７－アミンの新規結晶形

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128231A1 (fr) * 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Dérivés de pyrimidine
WO2010025138A2 (fr) * 2008-08-29 2010-03-04 Hutchison Medipharma Enterprises Limited Composés pyrimidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2373197C2 (ru) * 2004-03-30 2009-11-20 Тайсо Фармасьютикал Ко., Лтд. Пиримидиновые производные, обладающие активностью в отношении мсн
WO2007035309A1 (fr) 2005-09-15 2007-03-29 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
CN101289444B (zh) * 2007-04-16 2012-01-04 和记黄埔医药（上海）有限公司 一种嘧啶衍生物及其医药用途
CN102070618B (zh) 2009-11-23 2013-08-21 和记黄埔医药（上海）有限公司 一种化合物及其晶体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128231A1 (fr) * 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Dérivés de pyrimidine
WO2010025138A2 (fr) * 2008-08-29 2010-03-04 Hutchison Medipharma Enterprises Limited Composés pyrimidine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011060746A1 *

Also Published As

Publication number Publication date
MX2012005926A (es) 2012-11-23
US20120270889A1 (en) 2012-10-25
BR112012012138B1 (pt) 2023-02-07
US8946249B2 (en) 2015-02-03
JP2013511475A (ja) 2013-04-04
ES2529105T3 (es) 2015-02-16
JP5758399B2 (ja) 2015-08-05
AU2010321366B2 (en) 2014-07-24
CN102648194A (zh) 2012-08-22
CN102070618B (zh) 2013-08-21
WO2011060746A1 (fr) 2011-05-26
PL2504331T3 (pl) 2015-04-30
EP2504331B1 (fr) 2014-11-12
KR20120097526A (ko) 2012-09-04
CN102648194B (zh) 2014-10-29
KR101513784B1 (ko) 2015-04-20
CA2781066A1 (fr) 2011-05-26
CA2781066C (fr) 2014-09-16
US20140200232A1 (en) 2014-07-17
RU2507203C1 (ru) 2014-02-20
IN2012DN04868A (fr) 2015-09-25
US8658658B2 (en) 2014-02-25
AU2010321366A8 (en) 2012-07-05
NZ600266A (en) 2014-06-27
RU2012126112A (ru) 2013-12-27
DK2504331T3 (en) 2014-12-08
PT2504331E (pt) 2015-02-20
PH12012500992A1 (en) 2016-09-09
CN102070618A (zh) 2011-05-25
EP2504331A1 (fr) 2012-10-03
BR112012012138A2 (pt) 2017-03-07
AU2010321366A1 (en) 2012-06-14
MY161749A (en) 2017-05-15

Similar Documents

Publication Publication Date Title
EP2504331A4 (fr) Composé, certaines nouvelles formes de celui-ci, compositions pharmaceutiques de celui-ci et procédés de préparation et d'utilisation
EP2528441A4 (fr) Certains inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
EP2505586A4 (fr) Composé d'indole et utilisation pharmaceutique de celui-ci
IL212435A (en) Isoindulin compounds, their pharmaceutical compositions and their use in the preparation of drugs
EP2751086A4 (fr) Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d'utilisation de ces compositions
EP2279008A4 (fr) Compositions pharmaceutiques de paclitaxel, d'analogues de paclitaxel ou de conjugués de paclitaxel et procédés de préparation et d'utilisation correspondants
EP2506835A4 (fr) Compositions pharmaceutiques enrobées et compressibles, comprimés et procédés de fabrication associés
EP2448406A4 (fr) Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
EP2401264A4 (fr) Oligomères peptoïdes, compositions pharmaceutiques et leurs procédés d'utilisations
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
EP2144610A4 (fr) Comprimé de mélatonine et procédés de préparation et d'utilisation
EP2750677A4 (fr) Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d'utilisation de ces compositions
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
BRPI0923836A2 (pt) Composições farmacêuticas orais contendo opióide e métodos
PT3150198T (pt) Composições farmacêuticas de ácido 3-(6-(1-(2,2 difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzóico e sua administração
EP2424356A4 (fr) Composition pharmaceutique stable et ses procédés d'utilisation
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
EP2659883A4 (fr) Préparation de microcapsule de dérivés acylés d'alginate-chitosan, préparation et application de celle-ci
EP2474522A4 (fr) Agomélatine et compositions pharmaceutiques la contenant
EP2833879A4 (fr) Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
EA201300258A1 (ru) Композиции на основе налбуфина и их применение
EP2736337A4 (fr) Certains inhibiteurs de kynurénine-3-mono-oxygénase, compositions pharmaceutiques et leurs procédés d'utilisation
EP2154966A4 (fr) Benzimidazoles et compositions pharmaceutiques de ceux-ci
EP2536285A4 (fr) Dérivés d'imidazole fusionnés et substitués, compositions pharmaceutiques et procédés d'utilisation associés

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120615

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130315

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 403/12 20060101AFI20130311BHEP

Ipc: A61K 31/506 20060101ALI20130311BHEP

Ipc: A61P 9/00 20060101ALI20130311BHEP

Ipc: A61P 35/00 20060101ALI20130311BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140522

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 695672

Country of ref document: AT

Kind code of ref document: T

Effective date: 20141115

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20141202

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010020275

Country of ref document: DE

Effective date: 20141224

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2529105

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150216

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150109

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150400178

Country of ref document: GR

Effective date: 20150220

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20141112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150312

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602010020275

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: BE

Effective date: 20150506

26 Opposition filed

Opponent name: GENERICS (UK) LIMITED (TRADING AS MYLAN)

Effective date: 20150812

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141123

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101123

REG Reference to a national code

Ref country code: DE

Ref legal event code: R100

Ref document number: 602010020275

Country of ref document: DE

PLCK Communication despatched that opposition was rejected

Free format text: ORIGINAL CODE: EPIDOSNREJ1

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PLBN Opposition rejected

Free format text: ORIGINAL CODE: 0009273

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: OPPOSITION REJECTED

27O Opposition rejected

Effective date: 20161014

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141112

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251201

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20251106

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20251126

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251128

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251127

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20251128

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20251128

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20251119

Year of fee payment: 16

Ref country code: FI

Payment date: 20251125

Year of fee payment: 16

Ref country code: DK

Payment date: 20251125

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251125

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20251104

Year of fee payment: 16

Ref country code: BE

Payment date: 20251127

Year of fee payment: 16

Ref country code: GR

Payment date: 20251126

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20251127

Year of fee payment: 16

Ref country code: CH

Payment date: 20251201

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20251106

Year of fee payment: 16

Ref country code: IE

Payment date: 20251127

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20251112

Year of fee payment: 16

Ref country code: BG

Payment date: 20251113

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20251201

Year of fee payment: 16